The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions.
about
SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalinkUpdate on Advances in Research on Idiosyncratic Drug-Induced Liver InjuryApplication of routine electronic health record databases for pharmacogenetic researchPhenotype standardization for statin-induced myotoxicityPathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives.Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.Genome wide analysis of drug-induced torsades de pointes: lack of common variants with large effect sizesPharmacogenomics: Current State-of-the-ArtPhenotype standardization of angioedema in the head and neck region caused by agents acting on the angiotensin system.T cell-mediated hypersensitivity reactions to drugsPhenX RISING: real world implementation and sharing of PhenX measures.Relating human genetic variation to variation in drug responses.Parsing interindividual drug variability: an emerging role for systems pharmacology.Cardiovascular pharmacogenomics: the future of cardiovascular therapeutics?Drug-induced arrhythmia: pharmacogenomic prescribing?The International Serious Adverse Events Consortium (iSAEC) phenotype standardization project for drug-induced torsades de pointes.Clinical delivery of pharmacogenetic testing services: a proposed partnership between genetic counselors and pharmacists.Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management.Pharmacogenomics and patient care: one size does not fit all.Phenotype standardization for immune-mediated drug-induced skin injury.HLA and pharmacogenetics of drug hypersensitivity.Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review.Advances in the Pharmacogenomics of Adverse Drug Reactions.Aminoglycoside-induced nephrotoxicity in children.The International Serious Adverse Events Consortium's data sharing model.Antituberculosis Drug-Induced Adverse Events in the Liver, Kidneys, and Blood: Clinical Profiles and Pharmacogenetic Predictors.Drug-Induced Arrhythmia: Bridging the Gap Between Pathophysiological Knowledge and Clinical Practice.Institutional profile: the Wolfson Centre for Personalised Medicine, University of Liverpool, Liverpool, UK.
P2860
Q24598793-EC74393A-2633-403B-A9F5-2893878F977EQ26779078-670345E7-176C-4FFF-8DB5-921347B5045FQ26864747-B44AE6CB-E2E7-4EB2-8DC7-A642E2ABA448Q27020935-60BA107D-C990-4870-9F52-A499FA3CD566Q27690772-CE1AC75E-A7BC-4DA9-AB8D-84A6927426E8Q27692095-BB9F96DE-FB4B-49D9-82F1-AC37A03CAA34Q28534878-8CBFA6F6-DC50-486D-A104-B6DC4A266F19Q33891714-951A0294-8F3F-43F3-9401-CA9FF7F61DA8Q34232188-0926EFE7-DEBB-4CB1-8B2A-4DEC5F304715Q34971993-28B91303-18C4-4416-929F-749E3F080EE8Q35125895-3F9901A3-5A15-458E-B65B-4180BF077E96Q36252524-63DB39E4-8D48-4122-AD0D-B53E6D361909Q36417380-5D753A79-39C7-41A3-95A0-0A3D0C7CAC8DQ36487290-C204199F-1B88-41C7-8367-E774EA7B8BD1Q36512441-AECC03EB-2911-4882-84E1-C4E30FD13F7BQ36988256-64C35941-DD14-4FA7-99E3-497D4F5916ECQ37065155-8ED42A40-D9C4-4407-9F9E-908D0285F71FQ37613267-7834BF69-F40E-4939-ACF8-F0129589C33CQ37658586-79D15C54-C64F-474D-A9E7-F71BC01773BFQ37874437-766C24A7-656C-4EAD-9781-E5F72F397A3DQ38037649-9E43B847-D88B-4FD9-9DDA-591EF7DE4309Q38207944-B90B3F52-8ED3-4CBC-99D0-0C624EEBE7D9Q38663764-93200E0A-07CC-4174-AE78-7EFEDC767E7DQ38795059-88A1BBDC-F913-4D10-BEC8-C577168B2430Q45954445-F79F934A-54AF-4444-AC5F-99C174B28951Q47715776-F4C84812-BC42-4FA9-B349-A44D70ACCC11Q48302148-A4FCC6C0-1298-4E6B-A96A-8A213024DB62Q50848412-5B76688B-C4EB-4AFE-B092-8042E3A4C89D
P2860
The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The phenotype standardization ...... erious adverse drug reactions.
@en
The phenotype standardization ...... erious adverse drug reactions.
@nl
type
label
The phenotype standardization ...... erious adverse drug reactions.
@en
The phenotype standardization ...... erious adverse drug reactions.
@nl
prefLabel
The phenotype standardization ...... erious adverse drug reactions.
@en
The phenotype standardization ...... erious adverse drug reactions.
@nl
P2860
P50
P356
P1476
The phenotype standardization ...... serious adverse drug reactions
@en
P2093
P2860
P304
P356
10.1038/CLPT.2011.30
P407
P577
2011-06-01T00:00:00Z